MEMBER LOGIN


Follow MVCC on:
 Follow MVCC on Facebook

Welcome to MVCC

Founded in 1993, the Missouri Valley Cancer Consortium (MVCC) is a non-profit organization based in Omaha, Nebraska that receives federal funding designed to bring state-of-the-art cancer clinical trials to Omaha and Lincoln metropolitan and surrounding areas. The CCOP network, which was created in 1983, was developed by the National Cancer Institute (NCI) to facilitate cancer prevention research efforts. Over the years, the CCOP network has expanded beyond cancer prevention trials to include cancer treatment, symptom management, and quality-of-life clinical trials. MVCC received this Community Clinical Oncology Program (CCOP) designation from the NCI in 1993. As a member of the CCOP network, MVCC is part of a collaborative team of physicians, hospitals, and local clinics designed to give patients more options to treat their cancer, in the comfort of their family and local community.

The Missouri Valley Cancer Consortium aims to provide patients with the highest quality cancer treatment, symptom management and prevention clinical trials available today. Since the inception of the MVCC in 1993, the network of community physicians and hospitals has continued to expand to meet the needs of physician partners and patients. Through the successful collaboration of the research team and support of local physicians and hospitals, the MVCC has been able to provide even more clinical trial options for cancer patients.

View Clinical Trials

 


 

Clinical Trials

Trials New This Month

View Clinical Trials
Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity
CHANGE IN MAMMOGRAPHIC DENSITY WITH METFORMIN USE: A COMPANION STUDY TO NCIC STUDY MA.32
A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer
Phase I/II Trial of IMC-A12 in Combination with CCI-779 in Patients with Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients with Triple Negative Metastatic Breast Cancer
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)
View Clinical Trials
Missouri Valley Cancer Consortium
6818 Grover Street * Executive Plaza, Suite 200 * Omaha, NE 68106
(402) 991-8070